scorecardresearch
Saturday, August 16, 2025
TopicCDSCO

Topic: CDSCO

Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO

Last year, an ICMR panel even considered recommending all-India ban on popular painkiller amid concerns it could cause liver damage, which could turn life-threatening in some cases.

As CDSCO lifts suspension on eye drops designed to replace reading glasses, makers eye June launch

Doctors caution that the drug should be used only under strong and regular supervision of an ophthalmologist.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Why a govt-appointed panel has recommended a complete ban on popular painkiller nimesulide

First launched in Italy in 1985, Nimesulide is available in India under brand names like Nimuwin, Nimutab, Nimopen, Nisulid, Nimdase, Nodard Plus, Nicip, Nimcap, Nicip-P and Nimupain.

Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits

In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is sold as heartburn medicine under names Rantac, Aciloc & Zinetac.

Drug regulator considers making central nod mandatory for all antibiotics in India, even existing ones

This new proposal, being considered by CDSCO, comes in response to concerns over antimicrobial resistance emerging as a massive public health challenge across the globe, including in India.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns

Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a 'replacement for reading glasses' & due to possible health risks.

‘Unauthorised promotion’, risk of unsafe use: Why CDSCO revoked nod for eye drops to replace glasses

Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.

On Camera

Nobel committee, note how Trump allowed Munir to make nuclear threat against India from US soil

So far, India has responded to his threats with a measured, diplomatic, strategic, and multi-dimensional approach. Now, it needs to react firmly.

Modi’s ‘Diwali bonanza’ for the common man—next-gen GST reforms, lower tax on daily-use items soon

Finance ministry says the proposed revamp will focus on structural reforms, rate rationalisation & ease of living, & will be deliberated upon in the coming weeks.

What is Project Sudarshan Chakra, announced by Modi from ramparts of Red Fort

The project is meant to be a ‘protective shield that will keep expanding’, the PM said. It is on the lines of the ‘Golden Dome’ announced by Trump, it is learnt.

War of IAF, PAF doctrines: As Pakistan obsesses over numbers, India embraces risk, wins

Now that both IAF and PAF have made formal claims of having shot down the other’s aircraft in the 87-hour war in May, we can ask a larger question: do such numbers really matter?